WAY-103

WAY-103 is a truncated code name that typically refers to a series of research compounds developed by Wyeth (now part of Pfizer). The most common compounds associated with this identifier are **WAY-103,612** and **WAY-103,702**. WAY-103,612 is a potent and highly selective antagonist of the alpha-1A adrenergic receptor, which was primarily investigated for the treatment of benign prostatic hyperplasia (BPH) due to its ability to relax smooth muscle in the prostate and bladder neck without significant cardiovascular side effects. WAY-103,702 is a potent and selective 5-HT1A receptor agonist that has been studied for its neuroprotective properties, particularly in the context of ischemic stroke and traumatic brain injury. While these compounds served as important pharmacological tools in preclinical research, they did not advance to widespread clinical use or regulatory approval.